Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:00 PM
Ignite Modification Date:
2025-12-24 @ 1:00 PM
NCT ID:
NCT06164561
Eligibility Criteria:
Inclusion Criteria:
* Patients with primary myelofibrosis or myelofibrosis secondary to myeloid tumors were diagnosed according to the diagnostic criteria of who 2022.
* Stable vital signs, ECOG score ≥ 2 points, tolerate and cooperate to complete 18F-FDG PET/CT and 18F-FAPI PET/MRI examination.
* The interval between imaging ,hematologic, cytogenetic and pathology was \< 2 weeks.
* Willing to accept 18F-FDG PET/CT and 18F-FAPI PET/MRI , sign the informed consent.
Exclusion Criteria:
* Inability or unwillingness to provide informed consent.
* Other malignancies, autoimmune diseases, or chronic active infections were diagnosed within 1 year before the diagnosis of myelofibrosis.
* Current infection was present within 1 week before PET examination.
* Pregnant or lactation.
* Unable to follow protocol to complete follow-up.
* Have received glucocorticoid therapy within 2 weeks before PET imaging examination.
* Using granulocyte colony-stimulating factor (G-CSF) within 4 weeks prior to PET imaging.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT06164561
Study Brief:
Protocol Section:
NCT06164561